2Nicholls MG. Prevention of heart failure. Medical Progress 1998;3(2) :22--23.
3Colucci WS. The effects of norepinephrine on myocardial biology: implications for the therapy of heart failure. Clin Cardiol 1998;21(12 Suppl 1) :s120--s124.
4Christopher TA, Lopez BL, Ma XL, et al. Effects of a hydroxylated metabolite of the β- adrenoreceptor antagonist, carvedilol, on pcst-ischemic tissue injury. Br J Pharrnacol 1998 ; 123(2) : 292--298.
5Ruffolo RR, Feuerstein GZ. Carvedilol preclinical profile and mechanisms of action in preventing the progression of congestive heart failure. Eur Heart J 1998; 19(Suppl B): SB19--SB24.
6Feuerstin GZ, Bril A, Ruffolo RR. Protective effects of carvedilol in the myoeardium. Am J Cadiol 1997; 80(11A) :41L--45L.
7Hamm CW, Ravkide J, Gerhardt W, et al. The prognostic value of serum troponin T in unstable angina. New Engl J Med 1992 ; 14(3) : 150--155.
8Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997;336(16) :1131--1141.
9Amain H, Seigo I. Apoptosis: Basic mechanisms and implications for cardiovascular disease. Circ Res 1998; 82 (11):1111--1129.
